Fiber product for medical cosmetology and preparation method thereof

Abstract

Some embodiments of the present invention provide a fibrous article for medical cosmetology comprising a poly-epsilon-caprolactone base layer and cellosilks distributed within the poly-epsilon-caprolactone base layer wherein the material of the cellosilks comprises polylactic acid, polyglycolic acid, a poly (lactic acid-glycolic acid) copolymer, poly (p-dioxanone), or a combination thereof. Some embodiments of the present disclosure also provide methods of making the fibrous article. Polylactic acid, polyglycolic acid, poly (lactic acid-glycolic acid) copolymer, poly (p-dioxanone) or a combination thereof with better mechanical strength are dispersed in poly-epsilon-caprolactone (poly-epsilon-caprolactone, PCL) in a cellosilk form, so that the mechanical strength of a pure PCL product is improved, the excellent cell affinity of the PCL is reserved, the degradation time interval can be regulated and controlled, and the degradation effect of the PCL product is improved. Therefore, the applicability of the fiber product is improved.

Description

Technical Field

[0001] The present invention relates to a fiber product for medical cosmetology and a preparation method thereof. Background Art

[0002] Biomedical fiber products have varying physical properties and biocompatibility requirements depending on their intended use. Poly-ε-caprolactone, due to its excellent biocompatibility, is often used in biomedical sutures and anti-adhesive membrane applications. However, due to its weak mechanical strength and slow degradation, the applicability and practicality of poly-ε-caprolactone fiber products are limited.

[0003] Therefore, how to provide fiber products with improved mechanical strength, controllable degradation time course, and good biocompatibility is a topic that is actively studied by those skilled in the art. Summary of the Invention

[0004] The present invention provides fiber products for medical cosmetics and methods for preparing these fiber products. By regulating the materials and temperature used in the mixing and granulation process, a material with excellent mechanical strength can be dispersed in poly-ε-caprolactone in the form of fibers. Consequently, the fiber products not only possess the excellent cell affinity of poly-ε-caprolactone, but also, through the addition of fibers, further enhance the mechanical strength of the fiber products and enable controllable degradation timelines.

[0005] Some embodiments of the present invention provide a fiber product for medical cosmetology, comprising a poly-ε-caprolactone base layer and fiber filaments, wherein the fiber filaments are distributed in the poly-ε-caprolactone base layer, wherein the material of the fiber filaments comprises polylactic acid, polyglycolic acid, poly(lactic acid-glycolic acid) copolymer, polydioxanone or a combination thereof.

[0006] In some embodiments, the weight ratio of the poly-ε-caprolactone base layer to the fiber filaments is from 10:90 to 99:1.

[0007] In some embodiments, the fiber filament comprises a plurality of fiber staples, wherein each fiber staple has a length between 100 microns and 2500 microns.

[0008] In some embodiments, the fiber filaments have a diameter between 5 microns and 100 microns.

[0009] In some embodiments, the fiber product is a wire or a film, wherein the diameter of the wire is between 200 microns and 1000 microns, and the thickness of the film is between 200 microns and 1000 microns.

[0010] Some embodiments of the present invention also provide a method for preparing fiber products for medical cosmetology, comprising: a melt spinning step, performing a melt spinning process on the spinning raw materials to obtain fiber filaments, wherein the spinning raw materials comprise polylactic acid, polyglycolic acid, poly(lactic acid-glycolic acid) copolymer, polydioxanone or a combination thereof; a mixing and granulation step, mixing and granulating the fiber filaments and poly-ε-caprolactone to form a fiber masterbatch, wherein the temperature of the mixing and granulation step is lower than the melting point of the fiber filaments and higher than the melting point of poly-ε-caprolactone; and a molding step, molding the fiber masterbatch to obtain a fiber product.

[0011] In some embodiments, after the melt spinning step, the method for preparing a fiber product further comprises: cutting the fiber filaments into a plurality of fiber staples.

[0012] In some embodiments, the mixing and granulating step comprises mixing and granulating the fiber filaments and poly-ε-caprolactone at a weight ratio of 10:90 to 99:1.

[0013] In some embodiments, the forming step comprises subjecting the fiber masterbatch to a spinning process, so that the fiber masterbatch is formed into a wire.

[0014] In some embodiments, the forming step includes subjecting the fiber masterbatch to a film-drawing process, so that the fiber masterbatch is formed into a film material. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Various aspects of the present invention will be best understood from the following detailed description when read in conjunction with the accompanying drawings. It should be noted that, in accordance with standard practice in the industry, the various features are not drawn to scale. Indeed, the dimensions of the various features may be arbitrarily increased or decreased for clarity of discussion.

[0016] Figure 1 Schematic cross-sectional views of fiber products according to some embodiments of the present invention are shown.

[0017] Figure 2A Schematic diagram illustrating that the fiber product in some embodiments of the present invention is a wire.

[0018] Figure 2B Schematic diagram illustrating that the fiber product in some embodiments of the present invention is a membrane.

[0019] Figure 3 A flow chart is shown showing a method for preparing a fiber product according to some embodiments of the present invention.

[0020] Figure 4AA graph depicts the remaining weight percentage trend of poly-ε-caprolactone (PCL) / poly(lactic acid-co-glycolic acid) copolymers (where the molar ratio of lactic acid to glycolic acid in PLGA is 10:90) wires in some embodiments of the present invention during an accelerated degradation test.

[0021] Figure 4B A trend chart showing the remaining weight percentage of poly-ε-caprolactone (PCL) / polydioxanone (PDO) wires in an accelerated degradation test according to some embodiments of the present invention is shown.

[0022] Wherein, the reference numerals:

[0023] 100: Fiber products

[0024] 110: Poly-ε-caprolactone base layer

[0025] 120: Fiber

[0026] 200: Preparation method

[0027] S210, S220, S230: Steps DETAILED DESCRIPTION

[0028] In order to realize the different features of the mentioned subject matter, the following summary of the invention provides many different embodiments. The following describes specific examples of components, numerical values, materials, configurations, etc. to simplify the present invention. Of course, these are merely examples and are not restrictive. For example, in the following description, forming a first feature on or above a second feature may include an embodiment in which the first feature and the second feature are formed in direct contact, and may also include an embodiment in which additional features are formed between the first feature and the second feature so that the first feature and the second feature may not be in direct contact. In addition, the present invention may repeat reference numbers and / or letters in various examples. This repetition is for the purpose of simplicity and clarity and does not itself represent the relationship between the various embodiments and / or configurations discussed.

[0029] The present invention provides fiber products for medical cosmetics and methods for preparing the same. By regulating the materials and temperature during mixing and granulation, polylactic acid (PLA), polyglycolic acid (PGA), poly(lactic acid-co-glycolic acid) copolymer (PLGA), polydioxanone (PDO), or a combination thereof, which exhibit superior mechanical strength (tensile strength), can be dispersed in poly-ε-caprolactone (PCL) in a filamentous form. This improves the mechanical strength of pure PCL products, allowing the fiber products to retain PCL's excellent cell affinity while also enabling controlled degradation timelines, thereby enhancing the product's applicability.

[0030] First, please refer to Figure 1 , which shows a schematic cross-sectional view of the fiber product 100.

[0031] Fiber product 100 includes a poly-ε-caprolactone base layer 110 (PCL base layer 110) and fiber filaments 120. Fiber filaments 120 are distributed within PCL base layer 110, wherein the material of fiber filaments 120 includes PLA, PGA, PLGA, PDO, or a combination thereof. It should be emphasized that by dispersing fiber filaments 120 (made of PLA, PGA, PLGA, PDO, or a combination thereof) with superior mechanical strength within PCL with superior cell affinity, fiber product 100 not only has good cell affinity but also has enhanced mechanical strength through fiber filaments 120.

[0032] Furthermore, because PLA, PGA, PLGA, or PDO and PCL degrade at different rates [PLA, PGA, PLGA, or PDO degrades faster (PLA degrades in approximately 2 years, PGA degrades in approximately 4 weeks, PLGA degrades in approximately 1 month to 18 months, and PDO degrades in approximately 6 months), while PCL degrades slower (degradation takes approximately more than 2 years)], compared to structures prepared by coating PCL on the surface of PLA, PGA, PLGA, PDO, or a combination thereof, or by directly mixing or co-extruding PLA, PGA, PLGA, PDO, or a combination thereof with PCL in the same form, the present invention, by dispersing PLA, PGA, PLGA, or PDO fibers 120 on a PCL base layer 110 and coating the fibers 120 with the PCL base layer 110, can extend and regulate the degradation time and improve the problem of uneven degradation rates that occurs when PCL is coated on the surface of PLA, PGA, PLGA, PDO, or a combination thereof.

[0033] It is worth mentioning that, since PCL has excellent cell affinity, compared with the design of a structure prepared by directly mixing or co-extruding PLA, PGA, PLGA, PDO or a combination thereof with PCL in the same form, the present invention uses PCL to coat the fiber filament 120 and exposes the PCL to the outside, which can enhance the cell affinity of the fiber product 100.

[0034] In some embodiments, the weight ratio of the PCL base layer 110 to the fiber filaments 120 is 10:90 to 99:1. In some embodiments, the weight ratio of the PCL base layer 110 to the fiber filaments 120 is 10:90, 15:85, 20:80, 25:75, 30:70, 35:65, 40:60, 45:55, 50:50, 55:45, 60:40, 65:35, 70:30, 75:25, 80:20, 85:15, 90:10, 95:5, 99:1, or any value in between. If the weight ratio is too low, the PCL base layer 110 is difficult to form, while if the weight ratio is too high, the cell affinity, mechanical strength, and ductility of the fiber product 100 are reduced. In some embodiments, when the weight ratio of the PCL base layer 110 to the fiber filaments 120 is 90:10 to 75:25 relative to a weight ratio of 50:50 to 10:90, the PCL base layer 110 can have better mechanical strength, ductility, and cell affinity.

[0035] In some embodiments, the fiber filaments 120 include a plurality of fiber staples, wherein each fiber staple has a length between 100 microns and 2500 microns, for example, 100 microns, 200 microns, 300 microns, 400 microns, 500 microns, 600 microns, 700 microns, 800 microns, 900 microns, 1000 microns, 1250 microns, 1500 microns, 1750 microns, 2000 microns, 2250 microns, 2500 microns, or any value between the foregoing intervals. In some embodiments, the fiber filaments 120 have a diameter between 5 microns and 100 microns, for example, 5 microns, 10 microns, 20 microns, 30 microns, 40 microns, 50 microns, 60 microns, 70 microns, 80 microns, 90 microns, 100 microns, or any value between the foregoing intervals. If the length or diameter is too small, the effect of improving the mechanical strength is limited. If the length or diameter is too large, it is difficult to be evenly coated in the PCL base layer, thereby affecting the overall properties and the material cost is too high.

[0036] In some embodiments, see Figure 2AThe fiber product 100 is exemplified as a wire. The length of the wire can be determined according to actual needs. For example, the diameter of the wire can be between 200 μm and 1000 μm, for example, 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, 1000 μm, or any value in between.

[0037] In some embodiments, see Figure 2B The fiber product 100 is exemplified as a membrane. The thickness of the membrane can be determined according to actual needs. For example, the thickness of the membrane can be between 200 μm and 1000 μm, such as 200 μm, 300 μm, 400 μm, 500 μm, 600 μm, 700 μm, 800 μm, 900 μm, 1000 μm, or any value in between.

[0038] In some embodiments, the fiber product 100 can be used in the field of medical aesthetics, such as surgical filaments, anti-adhesive membranes, patch materials, tissue engineering scaffolds, and other medical materials, by adjusting the weight ratio between the PCL base layer 110 and the fiber filaments 120 according to actual application requirements to adjust the mechanical properties, cell affinity, or degradation rate.

[0039] Next, please refer to Figure 3 (Also auxiliary reference Figure 1 ), depicting a flow chart of a method 200 for preparing a fiber product 100, including steps S210 to S230.

[0040] Step S210 is a melt spinning step, in which a melt spinning process is performed on a spinning material to obtain fiber filaments 120 , wherein the spinning material includes PLA, PGA, PLGA, PDO or a combination thereof.

[0041] In some embodiments, the temperature in step S210 is higher than the melting point of the spinning material, allowing the spinning material to be reshaped into fiber filaments 120. For example, when PGL is used as the spinning material, since the melting point of PGL is 210°C to 215°C, the temperature in step S210 is higher than 215°C. When PDO is used as the spinning material, since the melting point of PDO is 110°C to 115°C, the temperature in step S210 is higher than 115°C.

[0042] In some embodiments, after step S210 (melt spinning step), the method 200 for preparing the fiber product 100 further includes cutting the fiber filaments 120 into a plurality of fiber staples. Cutting the fiber filaments 120 into fiber staples can improve the dispersion of the fiber filaments 120 in the PCL base layer 110. In some embodiments, the length of each fiber staple is between 100 microns and 2500 microns.

[0043] Step S220 is a mixing and granulation step, in which the fiber filaments 120 and PCL are mixed and granulated to form a fiber masterbatch. The temperature in step S220 (mixing and granulation step) is lower than the melting point of the fiber filaments 120 and higher than the melting point of PCL (60°C to 65°C). In some embodiments, the temperature of the mixing and granulation step is between 60°C and 215°C, and the temperature can be adjusted based on the material of the selected fiber filaments 110.

[0044] It should be emphasized that the mixing and granulation temperature is designed so that only the PCL melts during the mixing and granulation process, while the fiber filaments 120 (or fiber staples) do not melt and maintain their original shape. This allows the fiber filaments 120 to be evenly dispersed and coated within the PCL. Therefore, the fiber filaments 120 maintain their original shape within the fiber masterbatch, further enhancing the mechanical strength of the subsequent fiber product 100.

[0045] Furthermore, compared to processes that directly mix or co-extrude PLA, PGA, PLGA, PDO, or a combination thereof with PCL in the same form, the present invention, through temperature control and selection of fiber materials, can alleviate concerns about PCL degradation caused by high temperatures (greater than the melting point of the fiber) and the problem of uneven degradation rates that arise in processes involving mixing or co-extrusion at high temperatures (greater than the melting point of the fiber).

[0046] In some embodiments, step S220 (mixing and granulating step) includes mixing and granulating the fiber filaments 120 and PCL at a weight ratio of 10:90 to 99:1. For example, the fiber filaments 120 and PCL are mixed and granulated at a weight ratio of 10:90, 15:85, 20:80, 25:75, 30:70, 35:65, 40:60, 45:55, 50:50, 55:45, 60:40, 65:35, 70:30, 75:25, 80:20, 85:15, 90:10, 95:5, 99:1, or any value in between. If the weight ratio is too low, the fiber masterbatch is difficult to form and the cell affinity is reduced. If the weight ratio is too high, the mechanical strength of the subsequent fiber product 100 is reduced. In some embodiments, when the weight ratio of PCL to the fiber filament 120 is 90:10 to 75:25 relative to a weight ratio of 50:50 to 99:1, the subsequent fiber product 100 can have better mechanical strength, ductility, and cell affinity.

[0047] Step S230 is a molding step, in which the fiber masterbatch is molded to obtain the fiber product 100. Those skilled in the art can mold the fiber masterbatch into the desired fiber product 100 according to actual application requirements.

[0048] In some embodiments, step S230 (forming step) includes subjecting the fiber masterbatch to a spinning process to form the fiber masterbatch into a wire. In some embodiments, step S230 (forming step) includes subjecting the fiber masterbatch to a film drawing process to form the fiber masterbatch into a film.

[0049] In the following description, multiple embodiments of the present invention are listed and various analyses are performed to verify the efficacy of the present invention.

[0050] Example 1: PCL / PLGA Wire and PCL / PDO Wire

[0051] 1. Preparation Method

[0052] Although PCL filaments have excellent cell affinity, they are limited by poor mechanical properties (poor tensile strength). To improve the mechanical properties of PCL filaments, PCL and PLGA and PDO, which have strong tensile strength, were co-prepared into PCL / PLGA filaments and PCL / PDO filaments. The specific steps are as follows.

[0053] First, PLGA (LA to GA molar ratio of 10:90) and PDO were selected as spinning raw materials. PLGA (melting point 210°C to 215°C) and PDO (melting point 110°C to 115°C) were melt-spun to obtain PLGA fiber filaments and PDO fiber filaments with wire diameters ranging from 10 microns to 99 microns. PLGA fiber filaments and PDO fiber filaments with wire diameters ranging from 70 microns to 99 microns were selected for subsequent processes. Next, the PLGA fiber filaments and PDO fiber filaments were cut into fiber staples with a length of less than 2000 microns, respectively, to obtain PLGA fiber staples and PDO fiber staples.

[0054] Next, the PLGA fiber staples and the PDO fiber staples are respectively mixed and granulated with PCL at a temperature higher than the melting point of PCL (60°C to 65°C) and lower than the melting point of PLGA or PDO. During the process, PCL dissolves and covers the PLGA fiber staples and PDO fiber staples while maintaining their original staple morphology, thereby obtaining PCL / PLGA fiber masterbatch (PLGA fiber staples distributed in PCL) and PCL / PDO fiber masterbatch (PDO fiber staples distributed in PCL). The mixing and granulation temperature of the PLGA fiber staples and PCL is 180°C to 200°C, and the mixing and granulation temperature of the PDO fiber staples and PCL is 90°C to 100°C.

[0055] Next, the PCL / PLGA fiber masterbatch and the PCL / PDO fiber masterbatch were respectively subjected to spinning processes to obtain one-piece composite fiber wires (PCL / PLGA wires and PCL / PDO wires, the poly-ε-caprolactone base layer was respectively coated with PLGA fiber staples or PDO fiber staples, so that the PLGA fiber staples or PDO fiber staples were distributed in the poly-ε-caprolactone base layer). The wire selected in this embodiment has a wire diameter of 400 μm to 499 μm.

[0056] 2. Performance Testing

[0057] 2.1 Test Groups

[0058] According to the preparation method in point 1 above and the ratios in Table 1 below, PCL / PLGA wires and PCL / PDO wires with different material ratios were prepared.

[0059] Table 1

[0060]

[0061]

[0062] Note 1: The molecular weight of PCL used in the examples is 270,000 / mol.

[0063] Note 2: The PLGA used in the examples (LA to GA molar ratio of 10:90) has an intrinsic viscosity (IV) of 1.25 dL / g.

[0064] Note 3: The PDO used in the examples has an intrinsic viscosity (IV) of 1.80 dL / g.

[0065] 2.2 Mechanical properties and cell affinity

[0066] Next, the wires listed in Table 1 were used to perform mechanical properties (tensile strength and elongation) tests and cell proliferation tests to confirm the mechanical properties and cell affinity of each group of wires. The tensile strength and elongation were based on the tensile strength / physical test in the United States Pharmacopoeia 37. <881> (The United States Pharmacopeia 37, Tensile strength / physical tests <881> ) is the value measured by the tensile test performed.

[0067] The cell proliferation test process is basically based on ISO 10993 specifications and includes the following steps: First, 0.02g of each group of wires are placed in each well of the cell culture plate. Then, fibroblast L929 cells are cultured in α-MEM (Minimal Essential Medium, MEM) containing 10% horse serum and 1x10 5 A cell culture medium containing a fibroblast cell line (L929 cell line) was seeded into each well and cultured at 37°C for 5 days. Next, the cell viability of each group was measured using the MTS Cell Proliferation Assay Kit. Using Comparative Example 2 (TGL100, 100% PLGA) and Comparative Example 3 (TDO100, 100% PDO), which have lower cell affinity, as baseline values, the cell proliferation rate (%) of each group was calculated as [(the number of cells in each group minus the baseline number of cells) / the baseline number of cells].

[0068] The results of the mechanical properties (tensile strength and elongation) test and the cell proliferation test are shown in Table 2.

[0069] Table 2

[0070]

[0071] First, in terms of tensile strength, it can be observed in the comparative examples that the tensile strengths of the TGL100 group (100% PLGA) and the TDO100 group (100% PDO) are significantly better than those of the TCL100 group (100% PCL).

[0072] Further observation of the test cases revealed that the tensile strength of the TCGL10 group (90% PCL + 10% PLGA) and the TCDO10 group (90% PCL + 10% PDO) was significantly improved compared to the TCL100 group (100% PCL) with only PCL added.

[0073] Furthermore, surprisingly, the researchers discovered that as the weight percentage of PLGA or PDO (which exhibit superior tensile strength) increased (from 10% to 50%), the tensile strength of the PCL / PLGA and PCL / PDO filaments gradually decreased. Specifically, for PCL / PLGA filaments, the tensile strength decreased from the TCGL10 group (90% PCL + 10% PLGA), to the TCGL25 group (75% PCL + 25% PLGA), to the TCGL50 group (50% PCL + 50% PLGA). For PCL / PDO filaments, the tensile strength decreased from the TCDO10 group (90% PCL + 10% PDO), to the TCDO25 group (75% PCL + 25% PDO), to the TCDO50 group (50% PCL + 50% PDO). Therefore, the tensile strength of composite filaments cannot be determined solely from the properties and content of the individual composite materials and requires experimental testing to confirm.

[0074] Specifically, the tensile strength trends shown in Table 2 above may be due to the fact that increasing the weight percentage of PLGA or PDO fiber staples to 50% (or higher) reduces the PCL content. This results in insufficient continuous flowability of the PCL substrate during the composite wire molding process, poor dispersion of the fiber staples, and difficulty in their uniform coating within the PCL substrate, thus affecting the overall mechanical properties of the composite wire. Therefore, the results in Table 2 provide an optimal ratio range that balances biocompatibility and mechanical properties.

[0075] Next, in terms of elongation, it can be observed in the comparative examples that the elongation of the TGL100 group (100% PLGA) and the TDO100 group (100% PDO) is significantly better than that of the TCL100 group (100% PCL).

[0076] Further observation of the test examples shows that as the weight percentage of PLGA or PDO with lower elongation increases (PLGA or PDO increases from 10% to 50%), the elongation of the PCL / PLGA wire or PCL / PDO wire gradually decreases.

[0077] Next, in terms of fibroblast proliferation rate, it can be observed in the comparative example that compared with the TGL100 group (100% PLGA) and the TDO100 group (100% PDO), the fibroblast proliferation rate of the TCL100 group (100% PCL) increased by 90%, indicating better cell affinity.

[0078] Further observation of the test examples revealed that as the weight percentage of PLGA or PDO with lower cell affinity increased (from 10% to 50%), the fibroblast proliferation rate of the PCL / PLGA or PCL / PDO filaments gradually decreased.

[0079] Therefore, according to Table 2, it can be concluded that, compared with pure PCL wires, when 10% to 25% of PLGA fiber staples or PDO fiber staples are introduced into PCL wires, the composite wires (PCL / PLGA wires, PCL / PDO wires) can not only maintain the good cell affinity of PCL, but also the PLGA fiber staples or PDO fiber staples can contribute to their mechanical properties, further improving the strength (tensile strength) of the composite wires.

[0080] 2.3 Degradability (accelerated degradation test)

[0081] In order to test the degradability of PCL / PLGA wires and PCL / PDO wires, the aforementioned groups of wires were vacuumed and cut into 1 cm pieces according to the international standard ISO 10993-13. They were immersed in a phosphate buffered saline solution (PBS) with a pH of 7.4 so that the volume of PBS divided by the surface area of the wires fell between the standard 1 ml / mm2 and 6 ml / mm2. Then, the PBS containing the wires was placed at 50°C for reaction. The wires were taken out individually after 7 days, 14 days, 21 days, and 28 days. After the surface of the wires was washed with double distilled water, they were placed at 50°C for drying for 24 hours, and then vacuumed for 24 hours. Finally, the weight of the wires before and after the experiment was weighed, and the remaining weight percentage of the wires was calculated using the following formula. According to the results in Table 3, the graph was drawn. Figure 4A as well as Figure 4B .

[0082] Remaining weight percentage (%) = weight after degradation (weight after cleaning and drying) / initial weight x 100%

[0083] Table 3

[0084]

[0085]

[0086] Please refer to Figure 4A(PCL / PLGA filaments), it can be observed that the degradation rate of the TCL100 group (100% PCL) is the slowest, and the degradation rate of the TGL100 group (100% PLGA) is the fastest. In the composite filament part, from the TCGL10 group (90% PCL + 10% PLGA), the TCGL25 group (75% PCL + 25% PLGA) to the TCGL50 group (50% PCL + 50% PLGA), the degradation rate of the PCL / PLGA filaments gradually increases with the increase of the PLGA (fast degradation rate) content.

[0087] Please refer to Figure 4B For PCL / PDO filaments, the degradation rate of the TCL100 group (100% PCL) was the slowest, while the degradation rate of the TDO100 group (100% PDO) was the fastest. For composite filaments, the degradation rate of the PCL / PDO filaments gradually increased with the increase in the content of PDO, which has a faster degradation rate (faster degradation rate).

[0088] Therefore, the degradation rate of the composite wire can be adjusted by adjusting the ratio of PCL and PLGA or PDO according to actual application requirements.

[0089] Example 2: PCL / PLGA membrane and PCL / PDO membrane

[0090] 1. Preparation Method

[0091] The preparation method here is basically similar to the preparation method of point 1 of Example 1. The difference is that after obtaining the PCL / PLGA fiber masterbatch and the PCL / PDO fiber masterbatch, the spinning process is replaced by a film drawing process to obtain the composite membrane material (PCL / PLGA membrane material and PCL / PDO membrane material). The membrane material thickness set in this example is 200 μm to 249 μm.

[0092] 2. Performance Testing

[0093] 2.1 Test Groups

[0094] According to the preparation method in point 1 above and the ratios in Table 4 below, PCL / PLGA membranes and PCL / PDO membranes with different material ratios were prepared.

[0095] Table 4

[0096]

[0097]

[0098] Note 4: PCL, PLGA, and PDO used in Table 4 are the same as those in Table 1.

[0099] 2.2 Mechanical properties and cell affinity

[0100] Next, the membrane materials listed in Table 4 were used to perform mechanical property tests (tensile strength and elongation) using essentially the same method as in point 2.2 of Example 1. The results are shown in Table 5.

[0101] Table 5

[0102]

[0103] The film materials in Table 5 basically have a trend similar to that of the wire materials in Table 2 of Example 1.

[0104] In terms of tensile strength, it can be observed in the comparative examples that the tensile strength of the FGL100 group (100% PLGA) and the FDO100 group (100% PDO) is significantly better than that of the FCL100 group (100% PCL). Furthermore, as the weight percentage of PLGA or PDO (which have superior tensile strength) increases (from 10% to 50%), the tensile strength of PCL / PLGA and PCL / PDO filaments gradually decreases. Specifically, for PCL / PLGA membranes, the tensile strength decreases from the FCGL10 group (90% PCL + 10% PLGA), to the FCGL25 group (75% PCL + 25% PLGA), to the FCGL50 group (50% PCL + 50% PLGA). For PCL / PDO membranes, the tensile strength decreases from the FCDO10 group (90% PCL + 10% PDO), to the FCDO25 group (75% PCL + 25% PDO), to the FCDO50 group (50% PCL + 50% PDO). Therefore, the tensile strength of composite membranes cannot be determined solely from the properties and content of the individual composite materials and requires experimental testing to confirm.

[0105] The possible reasons for the tensile strength trends in Table 5 are similar to those explained above for the tensile strength trends in Table 2. Specifically, when the weight percentage of PLGA or PDO fiber staples increases to 50% (or higher), it becomes difficult for the fiber staples to be evenly coated within the PCL base layer, thus affecting the mechanical properties of the overall composite wire.

[0106] Next, in terms of elongation, the comparative examples show significantly better elongation for the FGL100 (100% PLGA) and FDO100 (100% PDO) groups compared to the FCL100 (100% PCL) group. Further observation of the test examples reveals that as the weight percentage of the lower-elongation PLGA or PDO increases (from 10% to 50%), the elongation of the PCL / PLGA or PCL / PDO membranes decreases.

[0107] Therefore, according to Table 5, it can be found that compared with pure PCL membranes, when 10% to 25% of PLGA fiber staples or PDO fiber staples are introduced into PCL membranes, the composite membranes (PCL / PLGA membranes, PCL / PDO membranes) can also maintain the good cell affinity of PCL, and at the same time, the strength (tensile strength) of the membranes can be further improved by using PLGA fiber staples or PDO fiber staples.

[0108] The features of some embodiments are summarized above so that those skilled in the art can better understand the viewpoints of the present invention. Those skilled in the art will appreciate that they can easily use the present invention as a basis for designing or modifying other processes and structures to achieve the same purpose and / or achieve the same advantages as the embodiments described herein. Those skilled in the art will also appreciate that such equivalent constructions do not depart from the spirit and scope of the present invention, and that various changes, substitutions, and modifications may be made without departing from the spirit and scope of the present invention.

Claims

1. A fiber product for medical cosmetology, characterized in that: Include: a poly-ε-caprolactone base layer; and The fiber filaments are distributed in the poly-ε-caprolactone base layer, wherein the material of the fiber filaments comprises polylactic acid, polyglycolic acid, poly(lactic acid-glycolic acid) copolymer, polydioxanone or a combination thereof. 2 . The fiber product for medical cosmetic use according to claim 1 , wherein the weight ratio of the poly-ε-caprolactone base layer to the fiber filament is 10:90 to 99:

1.

3. The fiber product for medical cosmetic use according to claim 1, wherein the fiber filament comprises a plurality of fiber short filaments, wherein the length of each of the fiber short filaments is between 100 μm and 2500 μm.

4. The fiber product for medical cosmetic use according to claim 1, wherein the diameter of the fiber filament is between 5 μm and 100 μm.

5. The fiber product for medical cosmetic use according to claim 1, wherein the fiber product is a wire or a film, wherein the diameter of the wire is between 200 μm and 1000 μm, and the thickness of the film is between 200 μm and 1000 μm.

6. A method for preparing a fiber product for medical cosmetic use, characterized in that: Include: a melt spinning step, performing a melt spinning process on a spinning raw material to obtain fiber filaments, wherein the spinning raw material comprises polylactic acid, polyglycolic acid, poly(lactic acid-glycolic acid) copolymer, polydioxanone or a combination thereof; a mixing and granulating step of mixing and granulating the fiber filaments and poly-ε-caprolactone to form a fiber masterbatch, wherein the temperature of the mixing and granulating step is lower than the melting point of the fiber filaments and higher than the melting point of the poly-ε-caprolactone; as well as The molding step is to mold the fiber masterbatch to obtain the fiber product.

7. The method for preparing a fiber product for medical cosmetic use according to claim 6, wherein after the melt spinning step, the method for preparing the fiber product further comprises: The fiber filament is cut into a plurality of fiber short filaments.

8. The method for preparing a fiber product for medical cosmetic use according to claim 6, wherein the mixing and granulating step comprises mixing and granulating the fiber filaments and the poly-ε-caprolactone in a weight ratio of 10:90 to 99:

1.

9. The method for preparing a fiber product for medical cosmetic use according to claim 6, wherein the forming step comprises subjecting the fiber masterbatch to a spinning process so that the fiber masterbatch is formed into a wire.

10. The method for preparing a fiber product for medical cosmetic use according to claim 6, wherein the molding step comprises subjecting the fiber masterbatch to a film-drawing process, so that the fiber masterbatch is molded into a film material.

Images